SeqOne S.A.S. news
SeqOne Genomics, provider of nextgeneration genomic analysis solutions for personalized medicine, announces the appointment of Hervé Pouzoullic as Chief Commercial Officer (CCO). He will lead the commercial development of the company to accelerate its growth and strengthen its international presence.
Hervé has more than 25 years of experience in sales, business development and general management. He worked at KPMG, Sanofi and, ThermoFisher Scientific in
SeqOne today announced the results of a long-standing research collaboration with Pr. Laurent Mesnard, Co-Director of the French National center for Thrombotic MicroAngiopathies (CNR-MAT), aimed at improving the diagnosis and management of patients suspected of suffering from thrombotic microangiopathies and atypical Hemolytic syndrome (aHUS). The program involved using Oxford Nanopore’s revolutionary technology to sequence patie
SeqOne Genomics, today announced that Michael Blum, Ph.D. is joining the company to lead its research and development department. He is tasked with driving SeqOne’s R&D strategy notably in the area of rare diseases and oncology through the use of machine learning and data science.
Michael started his career as a biostatistician and bioinformatician at the CNRS where he developed software solutions that enabled complex genomic data analysis for biologists and clinicians. He t
SeqOne Genomics, provider of next-generation genomic analysis solutions for personalized medicine is proud to announce a new strategic partnership with ILC Instrumentos de Laboratório Científicos to facilitate access to its genomic analysis solutions in Portugal. Through this partnership, ILC Instrumentos de Laboratório Científicos has been appointed as a value added distributor in Portugal.
Nicolas Philippe, CEO co-founder of SeqOne Gen
The round, led by Omnes, Merieux Equity Partners, together with the Software Club and existing investors, Elaia and IRDI Capital Investissement, will enable SeqOne Genomics to accelerate its international sales and the development of new collaborative genomic analysis tools to facilitate communications between different disciplines in the medical team, in order to improve patient outcomes in cancer and hereditary disease.
The company will intensify investments in the development of it